LivaNova PLC (LIVN)
| Market Cap | 4.30B +44.3% |
| Revenue (ttm) | 1.47B +12.4% |
| Net Income | 188.55M |
| EPS | 3.40 |
| Shares Out | 55.09M |
| PE Ratio | 22.93 |
| Forward PE | 17.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,377,456 |
| Open | 77.34 |
| Previous Close | 77.79 |
| Day's Range | 76.78 - 78.44 |
| 52-Week Range | 48.82 - 85.76 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 89.10 (+14.22%) |
| Earnings Date | Nov 4, 2026 |
About LIVN
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead th... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for LIVN stock is "Buy." The 12-month stock price target is $89.1, which is an increase of 14.22% from the latest price.
News
LivaNova Transcript: 2026 Global Healthcare Conference
Sustained double-digit growth is driven by talent, execution, and innovation, with new reimbursement and clinical data providing strong tailwinds. Margin expansion will be reinvested in OSA, while next-gen products and digital upgrades are set to drive future growth across epilepsy and cardiopulmonary segments.
LivaNova Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Core businesses in cardiopulmonary and epilepsy are driving sustainable growth, supported by innovation, improved reimbursement, and supply chain enhancements. Expansion into OSA with differentiated technology and a robust pipeline is expected to accelerate growth, while capital allocation focuses on reinvestment and selective M&A.
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare...
LivaNova price target raised to $90 from $87 at Piper Sandler
Piper Sandler raised the firm’s price target on LivaNova (LIVN) to $90 from $87 and keeps an Overweight rating on the shares. Following concerns over the U.S. cardiopulmonary Q2 result…
LivaNova selloff brings attractive entry point, says Mizuho
Mizuho believes the post-earnings selloff in shares of LivaNova (LIVN) provides an attractive entry point. After meeting with management, the firm believes the outlook for at least high-single-digit g...
LivaNova price target raised to $85 from $80 at Stifel
Stifel raised the firm’s price target on LivaNova (LIVN) to $85 from $80 and keeps a Buy rating on the shares. The optics of slowing U.S. cardiopulmonary growth are “more…
LivaNova price target raised to $93 from $81 at Needham
Needham raised the firm’s price target on LivaNova (LIVN) to $93 from $81 due to peer multiple expansion, while keeping a Buy rating on the shares. The firm notes the…
LivaNova Earnings Call Transcript: Q2 2026
Record quarterly revenue and EPS were achieved, driven by strong Cardiopulmonary and Epilepsy growth, leading to raised 2026 revenue and EPS guidance. Strategic investments in manufacturing and digital health are expected to support long-term growth, while a new supply agreement removes key constraints.
LivaNova Earnings release: Q2 2026
LivaNova released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
LivaNova Slides: Q2 2026
LivaNova has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
LivaNova Quarterly report: Q2 2026
LivaNova has published its Q2 2026 quarterly earnings report on August 5, 2026.
LivaNova raises FY26 adjusted EPS view to $4.30-$4.40 from $4.20-$4.30
FY26 consensus $4.25. LivaNova (LIVN) now expects full-year 2026 revenue to grow between 8%-9% versus 7%-8% prior on a constant-currency basis. Foreign currency is expected to be a tailwind of…
LivaNova reports Q2 adjusted EPS $1.26, consensus $1.09
Reports Q2 revenue $390.6M, consensus $380.58M. “In the second quarter, LivaNova (LIVN) delivered strong revenue growth driven by sustained performance in our Cardiopulmonary and Epilepsy businesses,”...
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the second quarter ended June 30, 2026 and rai...
LivaNova price target raised to $95 from $90 at Mizuho
Mizuho raised the firm’s price target on LivaNova (LIVN) to $95 from $90 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical device and…
LivaNova initiated with a Hold at Freedom Capital
Freedom Capital initiated coverage of LivaNova (LIVN) with a Hold rating and $81 price target The neurostimulation market is an attractive growth opportunity where small-to-mid cap players like LivaNo...
LivaNova to Announce Second-Quarter 2026 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5...
LivaNova price target raised to $92 from $83 at KeyBanc
KeyBanc raised the firm’s price target on LivaNova (LIVN) to $92 from $83 and keeps an Overweight rating on the shares. Last week’s attendance at the SLEEP APSS Meeting in…
LivaNova announces new data on PolySync programming from OSPREY study
LivaNova (LIVN) announced new data showing that use of its PolySync programming algorithm increased the cumulative apnea-hypopnea index response rate to 84.5% in patients with moderate to severe Obstr...
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm incre...
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company's Board of Directors a...
LivaNova Transcript: AGM 2026
The meeting was held virtually with strong shareholder participation and all quorum requirements met. Ten resolutions covering director elections, compensation, auditor appointments, and share repurchase were presented, with final results to be published. No shareholder questions were received.
LivaNova Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined sustained growth through reinvestment in core businesses, improved reimbursement, and manufacturing scale. VNS Therapy and Essenz upgrades are driving performance, while OSA and new product launches offer future upside. Margin discipline is maintained alongside strategic investments.
LivaNova appoints Liddy as Chief Legal Officer
LivaNova (LIVN) announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company’s global legal and compliance function and serve as a member…
LivaNova Appoints Anne Liddy as Chief Legal Officer
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August...